On June 16, Shandong Linuo Special Glass Co., Ltd. (Stock code: 301188, stock referred to as "Linuo Tebo") successfully applied for the issuance of convertible bonds. The refinancing plan
of Linotebo raised about 500 million yuan, all of which were used for the construction of the industrialization project of lightweight medicinal molded glass bottles (Class I).
In recent years, the market scale of pharmaceutical glass industry has grown rapidly. Especially with the application and promotion of high-end pharmaceutical products, the demand for pharmaceutical packaging materials such as borosilicate molded bottles has witnessed a blowout. Organizations predict that in the next 5 to 10 years, 30% -40% of pharmaceutical glass in China will be upgraded from low borosilicate glass and soda-lime glass to medium borosilicate glass, and the market space is expected to increase by 4-5 times.
Linuo Tebo has complete design and development capabilities of borosilicate special glass melting furnaces and personalized design and improvement technologies of key parts of glass furnaces. Since the establishment of the factory, it has devoted itself to the melting technology of borosilicate glass and the development of new products. After more than ten years of development, we have mastered a complete set of melting and forming technology, and according to market demand, we constantly update equipment and improve the level of technology, and the product quality has also been highly recognized by customers. At present, the
company has built and put into operation a new type of energy-saving glass melting all-electric melting furnace for the project of lightweight thin-walled high-grade medicinal glass bottles, with one furnace and two lines, which is molded by the company's self-developed & nbsp; Class I glass. The product conforms to the national standard YBB. The process of procurement, production, inspection and release of the product conforms to the standard requirements of ISO15378 system, which includes some GMP requirements. In addition, the lightweight design concept not only meets the quality requirements, but also meets the needs of pharmaceutical enterprises.
In addition, the company has passed a series of first-class standard system certification at home and abroad, and the production process and product quality and safety have been widely recognized. Linuo Tebo has the only pharmaceutical glass research base of the Pharmaceutical Packaging Association in China, and the laboratory has passed the national CNAS certification. As a core unit, the company also participated in the drafting of national standards for borosilicate 5.0 pharmaceutical glass, glass instruments and heat-resistant glassware. The total investment of the project raised by
the company is about 642 million yuan, and the construction period of the project is 16 months. After the project reaches the production capacity, it can form an annual production capacity of 46,600 tons of light medicinal molded glass bottles (Class I). In August last year, the Company completed and put into production the project of light weight, thin wall and high-grade pharmaceutical glass bottles for the production of medium borosilicate moulded bottles, and has taken the lead in carrying out the review and approval work related to the preparations of downstream pharmaceutical enterprises. At present, the above work is progressing smoothly, which is conducive to the rapid progress of the work after the project is put into production, the release of production capacity and the development of the market.
In the future, with the further development of high-end, energy-saving, environmental protection and lightweight glass products industry, as well as the continuous scale and standardization of the industry, Linuo Tebo will give full play to its competitive advantages, further expand and strengthen the market segments, and constantly enrich its products, so as to achieve greater results in the depth and breadth of the market.
浙公网安备33010802003254号